No Prescription |
 |
 | ||
|
Accolate Generic Zafirlukast |
|
| ||
No Prescription » Prescription Drugs 1 » Accolate Generic Zafirlukast Product Origin: EU (Turkey) This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English. Medical Information: Accolate helps prevent asthma attacks. It is prescribed for long-term treatment. Accolate (zafirlukast) is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. Available as a tablet it blocks the effects of substances which cause constriction of the airways build-up of mucus in the lungs and inflammation of the breathing passages. Accolate was the first LTRA to be marketed in the USA and is now approved in over 60 countries including the UK Japan Italy Spain Canada Brazil and China. Accolate is approved in the USA for adults and children aged 5 years and above. Accolate will not stop an asthma attack once it starts. You will still need to use an airway-opening medication when an attack occurs. Dosage:ADULTS The usual dose for adults and children 12 years of age and over is 20 milligrams twice a day. CHILDRENThe usual dose for children 7 to 11 years of age is 10 milligrams twice a day. Safety and effectiveness in children under 7 years of age have not been established. Buy Accolate Generic Zafirlukast and other Prescription Drugs 1 products online at Medstore. 3623
About Accolate Generic Zafirlukast: Product Type: Prescription Drugs 1 Accolate (Generic Zafirlukast ) Accolate (Generic Zafirlukast) Generic Zafirlukast 20mg 56 Tabs Generic Zafirlukast Accolate
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
